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Research
Systemic lupus erythematosus (SLE) is a 
chronic autoimmune disease of unclear 
etiology, with a prevalence as high as 1 in 
2,500 women (Bernatsky et al. 2007). It is 
characterized by an overactive immune system 
that targets normal tissue in nearly any body 
organ. The resulting inflammation causes 
dysfunction and damage; involvement of 
major organs such as the kidneys can be par­
ticularly devastating and even life­threatening 
(Bernatsky et al. 2007).
The factors driving SLE are complex, but it 
is clear that there are definite, albeit ill­defined, 
exogenous triggers. Different possible environ­
mental triggers have been considered, but at 
present there are relatively few relevant studies 
(Parks and Cooper 2006) and essentially no 
work has examined the effect of air pollution 
on SLE manifestations. This is an important 
knowledge gap, because there is a growing 
interest in pollution emissions and particulate 
matter (PM) exposures and their effects on 
health. This interest stems from recent data 
that have suggested that these exposures may 
be important triggers of systemic inflammation 
that could have important effects in terms of 
autoimmunity. Recent data have suggested 
that these exposures may be important triggers 
of systemic inflammation [for a review, see 
U.S. Environmental Protection Agency (EPA) 
2004] that could have important effects in 
terms of autoimmunity.
Our aim in this study was to evaluate the 
potential influence of PM air pollution on 
the clinical course of SLE. We have focused 
on the effects of variations in levels of fine 
ambient PM with median aerodynamic diam­
eter ≤ 2.5 µm (PM2.5). The main sources of 
PM2.5 in the region of the study include road­
vehicle emissions and industrial emissions. 
Such small particles enter the body through 
airways and can affect immune system 
pathways (U.S. EPA 2004).
Materials and Methods
Subjects and overview of health assessments. 
We studied subjects who were followed in 
a clinical registry at the Lupus Clinic of the 
McGill University Health Centre (MUHC). 
All patients in this registry cohort fulfilled the 
revised American College of Rheumatology 
(ACR) criteria for SLE (Hochberg 1997; Tan 
et al. 1982). Subjects in the cohort completed 
an annual evaluation that consisted of a review 
of symptoms, medications, physical find­
ings, and laboratory testing. The data were 
used to construct validated measures of disease 
activity [SLE Disease Activity Index, version 
2000 (SLEDAI­2K)] (Gladman et al. 2002) 
and damage [Systemic Lupus International 
Collaborating Clinics/ACR Damage Index 
(SLICC/ACR)] (Gladman et al. 2002). 
The SLEDAI­2K is a “weighted” index that 
provides a measurement of disease activity 
of the organ systems in SLE over a 10­day 
period before the annual evaluation. The 
index includes central nervous system features, 
vascular involvement, kidney disease, musculo­
skeletal disease, dermatological features, serosal 
involvement, immune system activity, hema­
tological features, and constitutional symp­
toms (see Appendix). Theoretically, patients 
can score a maximum of 105, but in prac­
tice, scores greater than 45 are unusual. In the 
present study, we analyzed data collected on 
patients who resided on the island of Montreal 
(Quebec,	Canada)	and	who	were	evaluated	
from January 2000 through September 2007. 
All subjects consented to be included in the 
registry, and studies were conducted under 
ethical approval from the MUHC.
We studied associations between PM2.5 
and the SLEDAI­2K total score. We were 
also specifically interested in the presence or 
absence of renal tubule cellular casts, which 
are a marker for severe kidney inflammation 
related to SLE, and the presence or absence 
of antibodies against double­stranded DNA 
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Ba c k g r o u n d: Systemic lupus erythematosus (SLE) is a chronic disease of unclear etiology, 
  characterized by an overactive immune system and the production of antibodies that may target nor-
mal tissues of many organ systems, including the kidneys. It can arise at any age and occurs mainly in 
women.
oB j e c t i v e: Our aim was to evaluate the potential influence of particulate matter (PM) air pollution 
on clinical aspects of SLE.
Me t h o d s : We studied a clinic cohort of SLE patients living on the island of Montreal, followed 
annually with a structured clinical assessment. We assessed the association between ambient levels of 
fine PM [median aerodynamic diameter ≤ 2.5 μm (PM2.5)] measured at fixed-site monitoring stations 
and SLE disease activity measured with the SLE Disease Activity Index, version 2000 (SLEDAI-2K), 
which includes anti–double-stranded DNA (anti-dsDNA) serum-specific auto  antibodies and renal 
tubule cellular casts in urine, which reflects serious renal inflammation. We used mixed effects regres-
sion models that we adjusted for daily ambient temperatures and ozone levels.
re s u l t s: We assessed 237 patients (223 women) who together had 1,083 clinic visits from 2000 
through 2007 (mean age at time of first visit, 41.2 years). PM2.5 levels were associated with anti-dsDNA 
and cellular casts. The crude and adjusted odds ratios (reflecting a 10-μg/m3 increase in PM2.5 aver-
aged over the 48 hr prior to clinical assessment) were 1.26 [95% confidence interval (CI), 0.96–1.65] 
and 1.34 (95% CI, 1.02–1.77) for anti-dsDNA antibodies and 1.43 (95% CI, 1.05–1.95) and 1.28 
(0.92–1.80) for cellular casts. The total SLEDAI-2K scores were not associated with PM2.5 levels.
co n c l u s i o n s: We provide novel data that suggest that short-term variations in air pollution may 
influence disease activity in established autoimmune rheumatic disease in humans. Our results add 
weight to concerns that pollution may be an important trigger of inflammation and autoimmunity.
key w o r d s : air pollution, antibodies, disease activity, PM2.5, SLE, SLEDAI-2K, systemic lupus 
erythematous. Environ Health Perspect 119:45–49 (2011).  doi:10.1289/ehp.1002123 [Online 
22 September 2010]Bernatsky et al.
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(anti­dsDNA). Anti­dsDNA antibodies are 
specific for SLE, although they are not pres­
ent in all patients, and correlate with various 
types of system involvement (musculoskele­
tal, hematological, immunological, and, most 
important, renal disease) (Mosca et al. 2006). 
In the clinical setting, serial measurements of 
anti­dsDNA antibodies are routinely performed 
to identify and predict SLE activity and disease 
flare­ups, although the utility of this approach 
in decision making and treatment remains 
under discussion (Tseng et al. 2006).
Disease activity measurements. The 
physical examinations of the SLE patients were 
performed by a specialist physician who (along 
with the patient) was blinded to the potential 
associations (pollution and disease activity) 
being tested. Hematological and immuno­
logical manifestations of SLE (including the 
presence or absence of anti­dsDNA anti­
bodies) were evaluated using venous periph­
eral blood samples collected between 0830 
and 1130 hours on the day of the assessment. 
Urinalyses (to assess kidney disease, includ­
ing microscopic observation of casts) were 
done on freshly voided specimens. The pres­
ence of anti­dsDNA was assessed, up to 2007, 
using a radioimmunoassay method based on 
the Farr technique (Manthorpe et al. 1978). 
Thereafter, an enzyme­linked immunosorbent 
assay technique was used (Farrzyme human 
high­avidity anti­dsDNA enzyme immuno­
assay kit; Binding Site, Birmingham, UK).
We studied the two specific laboratory 
measures (anti­dsDNA antibodies and 
renal casts, both of which contribute to the 
SLEDAI­2K total score) because they are 
well known as important markers of the 
most active and severe forms of SLE and may 
represent more objective elements of SLE 
activity (as opposed to the musculoskeletal 
manifestation of arthritis for example, which 
may be a subtle or even subjective finding). 
Furthermore, these laboratory elements were 
measured specifically on the day of the clini­
cal evaluation, in contrast with other compo­
nents of the SLEDAI­2K (e.g., dermatological 
manifestations and oral ulcers) that are scored 
positive if a patient reports that they were 
present at any time within the 10 days before 
the clinicial evaluation, even if they are absent 
at the time of the annual examination.
Measures of ambient PM2.5 and ozone 
  levels. Hourly measurements at fixed­site 
monitoring stations on the island of Montreal 
were obtained from the Environment Canada’s 
National Air Pollution Surveillance network 
(http://www.etc­cte.ec.gc.ca/napsdata). The 
networks use tapered­element oscillating 
microbalance and beta attenuation monitor 
samplers (Ville de Montréal 2010) for PM2.5 
measurements and ultraviolet absorption ana­
lyzers for ozone. Hourly PM2.5 concentrations 
were averaged across all Montreal stations; 
these mean hourly levels, averaged for the 24 hr 
preceding each clinical evaluation (from 1000 
hours the day before the clinical evaluation to 
0900 hours the day of the evaluation) and for 
up to 10 days before, were assigned to each 
patient. Ozone levels on the days before the 
evaluation dates were averaged over the 8 hr 
from 0900 to 1700 hours because ozone levels 
are highest during these hours. The median 
numbers of monitoring stations used to com­
pute the daily PM2.5 and ozone concentrations 
were 7 and 10, respectively.
Outdoor ambient temperatures. We com­
puted the mean of the outdoor temperatures 
for the 24 hr preceding each clinic evaluation 
and for prior days (from 1000 hours the day 
before the clinical evaluation to 0900 hours 
the day of the evaluation). Hourly tempera­
ture data were acquired from the Environment 
Canada Meteorological Centre located at the 
Pierre Elliott Trudeau International Airport 
(Dorval,	Quebec,	Canada), about 20 km from 
the city core (Environment Canada 2010).
Analysis. To analyze associations between 
PM2.5 exposure levels and SLEDAI­2K 
total score, anti­dsDNA antibodies, and uri­
nary casts, we used random intercept models   
for repeated­measures (longitudinal) data 
to account for correlations among repeated 
measures within individuals. Thus, the inter­
pretation of reported estimates is at the subject 
level. We used negative binomial mixed models 
for SLEDAI­2K total score and logistic mixed 
models to estimate associations with binary 
outcome variables (anti­dsDNA and renal 
casts). The SLEDAI­2K score is a discrete and 
an asymmetrical variable. As overdispersion 
was present in the distribution of this variable 
(likelihood ratio test, p < 0.001) that precluded 
the use of a Poisson model, so we used a nega­
tive binomial model. Measures of association 
[incidence rate ratios (IRRs) for SLEDAI­2K 
scores and odds ratios (ORs) for anti­dsDNA 
and renal casts] and their 95% confidence 
intervals (CIs) are presented as associations per 
10­µg/m3 increases in PM2.5 levels. Adjusted 
models included ozone levels [a potential risk 
factor for inflammation (e.g., Khatri et al. 
2009) that may vary with PM2.5] and ambient 
temperatures (to account for seasonal effects) 
averaged over the same time window as PM2.5.
Components of the SLEDAI­2K could be 
scored positive if present at any time within 
the 10 days preceding the assessment. Thus, 
to assess exposure–response relationships for 
total SLEDAI­2K scores, we assessed effects 
not only for PM2.5 levels on the day before the 
evaluation (average of hourly levels measured 
from 1000 hours the day before to 0900 hours 
on the day of the visit), but also for hourly 
averages of up to 10 days before the visit.
Age at SLE onset, age at time of physi­
cian assessment, smoking (ever vs. never), 
race/ethnicity (with separate dummy vari­
ables for Caucasian, black, or Asian), edu­
cation (whether or not the subject had any 
secondary schooling vs. ≤ 11 years), and 
daily use of immunomodulatory drugs 
(hydroxy  chloroquine, mycophenolate, oral 
or parenteral methotrexate, azathioprine, and 
prednisone) were evaluated as potential effect 
modifiers by adding product terms between 
each factor and PM2.5 to models. The effects 
Table 1. Characteristics of lupus patients (n = 237).
Characteristic Value
Age (years)
Disease onset 31.0 ± 13.8
First clinical visit 41.2 ± 15.5
Women 223 (94.1)
Race/ethnicity
Caucasians 150 (63.3)
Blacks 37 (15.6)
Asians 30 (12.7)
Other 20 (8.8)
Ever-smokera 101 (44.1)
Education ≤ high schoolb 55 (27.2)
No. of assessments per patient 4.6 ± 2.5
Data are reported as mean ± SD or n (%). 
aEight subjects were missing smoking status. bThirty-five 
subjects were missing education level.
Table 2. SLEDAI-2K scores, medication use, and environmental measurements on days of patients’ clinical 
evaluations (n = 1,083 visits).
Characteristic Value
Medication 
Hydroxychloroquine 729 (67.3)
Mycophenolate 119 (11.0)
Methotrexate (oral) 41 (3.8)
Methotrexate (parenteral) 11 (1.0)
Azathioprine 73 (6.7)
Prednisone 174 (16.1)
Disease activity
Total SLEDAI-2K score (n = 1,003) 4.5 ± 4.8 (0–28)
Anti-dsDNA, patient evaluations with positive assay (n = 957)  263 (27.5)
Renal tubule casts present on urinalysis (n = 861)  81 (9.4)
Disease damage SLICC/ACR score (n = 1,005) 1.9 ± 2.2
Environmental variables
PM2.5 (μg/m3) 10.0 ± 7.8 (1.1–54.9)
Ozone (μg/m3) 47.7 ± 23.7 (2.3–137.7)
Temperature (°C) 7.5 ± 11.4 (–21.5 to –28.8)
Data are reported as n (%) or mean ± SD (range). Air pollution and SLE activity
Environmental Health Perspectives  •  v o l u m e  119 | n u m b e r 1 | January 2011  47
of inter  actions were tested with α = 0.05. 
These variables did not vary with PM2.5 levels 
(data not shown) and so were not considered 
confounders. We performed all analyses with 
STATA (version 10.1; StataCorp LP, College 
Station, TX, USA).
Results
We studied 237 patients (223 women, 
14 men) with a mean age at the time of their 
first MUHC visit of 41.2 years old (range, 
18–83 years; Table 1). During the study 
period (January 2000–September 2007), 
each patient participated in an average of 4.6 
assessments that averaged 409 days apart. For 
this period, the PM2.5 levels rarely exceeded 
the PM2.5 Canadian objective of 30 µg/m3 
(Table 2).
The intraclass correlation for the three 
outcome variables within individual patients 
ranged from 0.12 to 0.40. IRR estimates did 
not clearly demonstrate a relationship between 
a 10­µg/m3 increase in PM2.5 and total 
SLEDAI­2K scores (Figure 1A), although our 
results suggested some potential effect with 
PM2.5 levels averaged over 10 days (not evident 
for PM2.5 levels on the day before the evalua­
tion; crude IRR for PM2.5 levels averaged over 
6 days = 1.09; 95% CI, 0.99–1.20). Anti­
dsDNA and urinary casts were significantly 
associated with PM2.5 levels shortly before 
the clinical visits (averaged over 24 or 48 hr 
before; Figure 1B,C). The crude OR relative 
to an increase in PM2.5 of 10 µg/m3 (48­hr 
averages) was 1.26 (95% CI, 0.96–1.65) for 
the presence of anti­dsDNA and 1.43 (95% 
CI, 1.05–1.95) for the presence of renal casts. 
Although not statistically significant, there was 
also a suggestion of some association between 
anti­dsDNA and PM2.5 levels averaged over 
10 days. Controlling for ambient temperatures 
and ozone levels had little influence (associa­
tion with PM2.5 levels averaged over 48 hr: 
anti­dsDNA, OR = 1.34; 95% CI, 1.02–1.77; 
renal casts, OR = 1.28, 0.92–1.80). Including 
potential effect modifiers in the model (e.g., 
medications and race/ethnicity) and examina­
tions for interactions failed to clearly dem­
onstrate important or consistent effects at 
α = 0.05.
Discussion
To our knowledge, the results presented 
here are the first to suggest that autoimmune 
inflammatory diseases such as SLE may be 
associated with variations in air pollutant levels. 
These findings add to a multitude of studies 
that have consistently related the adverse health 
effects (both acute and chronic) of ambient fine 
PM (Brook 2008; Calderón­Garcidueñas et al. 
2008; Ghio et al. 2000; U.S. EPA 2004). This 
study also adds weight to concerns that ambi­
ent air pollutants may be an important trigger 
of inflammation and autoimmunity.
Fine particles are believed to induce effects 
through inflammation and oxidative stress in 
the lungs when inhaled (U.S. EPA 2004). The 
smaller particles have also been suggested to 
enter the systemic circulation (Nemmar et al. 
2002), where they would be capable of caus­
ing widespread inflammation and oxidative 
stress (Shukla et al. 2000; U.S. EPA 2004). 
The proinflammatory circulating cytok­
ines generated upon air pollution exposure 
(Shoenfelt et al. 2009; van Eeden et al. 2001; 
Watterson et al. 2007) could plausibly act to 
trigger and/or heighten autoimmune disease.
Interestingly, there are two recent stud­
ies that have suggested road traffic and pol­
lution as triggers of autoimmune rheumatic 
diseases in humans, such as juvenile idiopathic 
arthritis (JIA) and rheumatoid arthritis (RA). 
In one study, Zeft et al. (2009) reported that 
increased concentrations of PM2.5 and stagnant 
air conditions were associated with significantly 
elevated risk of the onset of JIA in young chil­
dren. In another study, Hart et al. (2009) found 
that the risk of onset of RA for participants 
in the Nurses’ Health Study was higher for 
women who lived within 50 m of a major road 
than for those who lived 200 m or farther away; 
this finding suggests that pollution from traf­
fic is indeed an environmental risk factor for 
autoimmune diseases such as RA.
We observed associations between short­
term variations in PM2.5 levels (averaged over 
1–10 days) and anti­dsDNA and urinary 
casts that suggest acute effects. Although it 
is physiologically plausible for urinary casts 
and anti­dsDNA to vary on a daily basis with 
PM2.5 levels, studies are needed to document 
the kinetics of these features and to sup­
port the observed associations. Such knowl­
edge could help the understanding of their 
Figure 1. Associations between PM2.5 levels averaged over the day before the medical evaluations (from 
1000 hours the day before the evaluation to 0900 hours on the day of the evaluation) and up to the 10 days 
before, and SLEDAI-2K scores: total score (A), anti-dsDNA (B), and urinary casts (C). Associations are 
expressed per 10 μg/m3 of PM2.5. In each pair of data points, the first represents crude estimates and the 
second coefficients adjusted for ozone and temperature levels at the same exposure window as PM2.5. 
Whiskers represent 95% CIs.
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diagnostic value. We did not clearly demon­
strate an association between PM2.5 and over­
all SLEDAI­2K total scores; in part this may 
be due to the way the SLEDAI­2K is scored 
and to the fact that some features of disease 
activity could have been present early in the 
10­day window preceding the assessment (but 
not actually present at the time of the visit). 
Because the associations we observed were 
mainly with SLEDAI­2K lab measures (i.e., 
urinary casts and anti­dsDNA), further studies 
are needed to address whether fine PM levels 
are mainly associated with renal lupus activity 
or with the general disease activity.
There are several limitations associ­
ated with how we estimated exposure of 
our patients to PM2.5. We used PM2.5 daily 
regional averages because we did not have 
access to personal exposure information. We 
assumed that all subjects were in Montreal 
for the 10 days before their visits, but we did 
not have information on their actual location. 
Furthermore, outdoor ambient PM2.5 lev­
els may not adequately represent exposure 
of our patients because people are likely to 
spend most of their time indoors, where both 
indoor and outdoor PM2.5 sources contribute 
to indoor levels (World Health Organization 
2000). Future studies on the association 
between short­term variations in air pollu­
tion and inflammatory disease activity should 
address these limitations.
Because we did not study incident disease 
and because the patients under study were all 
from one tertiary care center, we cannot com­
ment on potential roles of long­term exposure 
or spatial variations in air pollution. Nor did 
we assess potential effects of pollution on the 
actual incidence of SLE. However, future 
work by our team, using population­based 
administrative data, will explore these issues.
Conclusion
Our data suggest that short­term variations in 
air pollution may influence disease activity in 
established autoimmune rheumatic disease in 
humans. Our results add weight to concerns 
that pollution may be an important trigger of 
inflammation and autoimmunity. Although 
further studies are needed to confirm these 
findings, we suspect that clinicians, health 
authorities, and patients may need to examine 
and address the potentially serious adverse 
health effects of pollution.
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Appendix 1. SLEDAI-2K data collection sheet. (Check weight in SLEDAI-2K score column if descriptor 
is present at the time of the visit or in the preceding 10 days.)
Weight 
(check) Descriptor Definition
8 ❏ Seizure Recent onset, exclude metabolic, infectious, or drug causes.
8 ❏ Psychosis Altered ability to function in normal activity due to severe disturbance in 
the perception of reality. Include hallucinations, incoherence, marked 
loose associations, impoverished thought content, marked illogical 
thinking, bizarre, disorganized, or catatonic behavior. Exclude uremia 
and drug causes.
8 ❏ Organic brain syndrome Altered mental function with impaired orientation, memory, or other 
intellectual function, with rapid onset and fluctuating clinical features, 
inability to sustain attention to environment, plus at least two of the 
following: perceptual disturbance, incoherent speech, insomnia or 
daytime drowsiness, or increased or decreased psychomotor activity. 
Exclude metabolic, infectious, or drug causes.
8 ❏ Visual disturbance Retinal changes of SLE. Include cytoid bodies, retinal hemorrhages, 
serous exudates or hemorrhages in the choroids, or optic neuritis. 
Exclude hypertension, infection, or drug causes.
8 ❏ Cranial nerve disorder New onset of sensory or motor neuropathy involving cranial nerves.
8 ❏ Lupus headache Severe, persistent headache; may be migrainous but must be 
nonresponsive to narcotic analgesia.
8 ❏ Cerebrovascular accident New onset of cerebrovascular accident(s); exclude arteriosclerosis.
8 ❏ Vasculitis Ulceration, gangrene, tender finger nodules, periungual infarction, 
splinter hemorrhages, or biopsy or angiogram proof of vasculitis.
4 ❏ Arthritis Two or more joints with pain and signs of inflammation (i.e., tenderness, 
swelling, or effusion).
4 ❏ Myositis Proximal muscle aching/weakness, associated with elevated creatine 
phosphokinase/aldolase or electromyogram changes or a biopsy 
showing myositis.
4 ❏ Urinary casts Heme granular or red blood cell casts.
4 ❏ Hematuria More than five red blood cells/high power field; exclude stone, infection, 
or other cause.
4 ❏ Proteinuria > 0.5 g/24 hr.
4 ❏ Pyuria More than five white blood cells/high power field; exclude infection.
2 ❏ Rash Inflammatory type rash.
2 ❏ Alopecia Abnormal, patchy, or diffuse loss of hair.
2 ❏ Mucosal ulcers Oral or nasal ulcerations.
2 ❏ Pleurisy Pleuritic chest pain with pleural rub or effusion or pleural thickening.
2 ❏ Pericarditis Pericardial pain with at least one of the following: rub, effusion, or 
electrocardiogram or echocardiogram confirmation.
2 ❏ Low complement Decrease in the complement proteins C3 and C4 or in total complement 
activity (CH50), below the lower limit of normal for testing laboratory.
2 ❏ Increased DNA binding Increased DNA binding by Farr assay above normal range for testing 
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